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Abstract
Aim: Patients with progressive chronic kidney disease (CKD) develop positive phosphate balance that is
associated with increased cardiovascular risk and mortality. Modification of dietary phosphate is a commonly
used strategy to improve outcomes but is complicated by the need for adequate dietary protein. Surprisingly,
the evidence for patient-level benefits from phosphate restriction is tenuous, and the justification for using any
phosphate binder for pre-dialysis patients is questionable.
Methods: The evidence for dietary phosphate modification was reviewed, along with the possible role of a
smart phone application (app) that provides information on phosphate, sodium, potassium and nutrients in
over 50 000 Australian foods. A pilot study of healthy participants assigned to dietetic advice and standard
diet sheets, or dietetic advice, diet sheets and use of the smart phone app was performed.
Results: Following baseline studies, 25 participants commenced the sodium and phosphate restricted diet.
After 2 weeks, both groups showed non-significant trends to reduction in urinary phosphate and sodium. App
users referred to information on the app more frequently than the control group participants referred to
written instructions, found referring to the app more convenient, felt they learned more new information,
were more motivated to maintain the diet and were more likely to recommend their information source to
family or friends (all P < 0.05).
Conclusions: Maintaining phosphate balance remains an important goal of CKD management, although diets
incorporating very low phosphate and protein contents may worsen patient outcomes. For selected patients, a
smart phone app may improve dietary acceptance and compliance.
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Abstract 
Background and objectives  
Patients with progressive chronic kidney disease (CKD) develop positive phosphate balance that is 
associated with increased cardiovascular risk and mortality. Modification of dietary phosphate is a 
commonly used strategy to improve outcomes but is complicated by the need for adequate dietary 
protein.  Surprisingly, the evidence for patient-level benefits from phosphate restriction is tenuous, 
and the justification for using any phosphate binder for pre-dialysis patients is questionable.  
Design, setting, participants, and measurements 
We review the evidence for dietary phosphate modification and the possible role of a smart phone 
application (app.) that provides information on phosphate, sodium, potassium and nutrients in over 
50,000 Australian foods. We performed a pilot study of healthy participants assigned to dietetic 
advice and standard diet sheets, or dietetic advice, diet sheets and use of the smart phone app. 
Results  
Following baseline studies, 25 participants commenced the sodium and phosphate restricted diet. 
After two weeks, both groups showed non-significant trends to reduction in urinary phosphate and 
sodium. App. users referred to information on the app. more frequently than the control group 
participants referred to written instructions, found referring to the app. more convenient, felt they 
learned more new information, were more motivated to maintain the diet and were more likely to 
recommend their information source to family or friends (all p<0.05), 
Conclusions 
Maintaining phosphate balance remains an important goal of CKD management, although diets 
incorporating very low phosphate and protein contents may worsen patient outcomes. For selected 
patients, a smart phone app. may improve dietary acceptance and compliance.  
 
Key words: phosphate, protein, dietary restriction, smart phone application, phosphate binders, 
cardiovascular risk 
Introduction. 
Phosphate is a natural component of foods rich in protein and mixed diets usually contain 12-14 mg 
per gram of protein 
1
.  The US Institute of Medicine has recommended  a dietary intake for 
maintaining phosphate balance and normal serum phosphate levels of 700 mg/day for healthy 
adults and up to 1250 mg/day for older children and pregnant women 
2
, and in Australia and New 
Zealand, the recommended daily intake for adults is 1000 mg/day 
3
.  Most studies suggest that 
protein intakes of 0.6 g/kg per day are adequate, with at least 50% as high biological value protein; 
containing essential amino acids in a proportion similar to that required by the body, and with a 
caloric intake sufficient to maintain body weight. However, higher protein intakes of 0.75 g/kg per 
day have been recommended for active young men and women and for elderly people who use 
protein less efficiently and have a lower lean mass 
4
.These recommendations also apply to patients 
with chronic kidney disease (CKD).  
 
Bioavailable phosphate. 
Phosphorus is organically bound and stored as phytate in grains, cereals and seeds. Humans and 
other non-ruminant animals lack the digestive enzyme phytase that is produced by bacteria in the 
gut of ruminants, and consequently humans are unable to digest phytate. This results in less than 
40% of phosphate from plant sources being bioavailable and the remainder being excreted. By 
comparison, phosphate derived from animal products such as meat, fish and milk is more readily 
absorbed
 5
, and the absorption of phosphate food additives approaches 100%. These additives are 
frequently used as food processing aids, as colour and flavour enhancers, to alter food texture and 
to increase shelf life. Sugary carbonated beverages have added phosphoric acid to sharpen flavour 
and to slow the growth of moulds and bacteria.  
 
The challenges of calculating dietary phosphate. 
Depending on the dietary source, around 60% of phosphate undergoes gastrointestinal absorption 
and 95% of the absorbed phosphate is renally excreted unless renal function is severely 
compromised. Intestinal phosphate absorption is responsive to levels of circulating 1,25-
dihydroxyvitamin D and prescribed calcitriol or other vitamin D receptor agonists (VDRAs). These 
drugs can increase active phosphate absorption to around 80% by increasing intestinal type II 
sodium-dependent phosphate co-transporter 2b (Npt2b) activity. With this in mind, the current 
Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder (MBD) 
guidelines no longer recommend the use of calcitriol/VDRAs for patients with CKD stages 3 to 5 and 





The varying bioavailability of phosphate between food sources and the effect of prescribed drugs on 
phosphate absorption can lead to the dietetic assessment of phosphate intake being inaccurate. In a 
study by Oenning et al. that compared dietary phosphate content using standard food tables and 
chemical analyses 
7
, food tables underestimated the phosphate content of diets by approximately 
350 mg/day. This inaccuracy was further emphasised in a recent study, which reported that 
traditional methods of calculating intake from food databases overestimated the true phosphate 
content of a vegetarian diet by 33%, although a fresh meat and milk product-based diet did match 
database predictions 
5
.  For patients with CKD, any reduction of dietary phosphate must be balanced 
against the maintenance of adequate dietary protein, energy and normal potassium values, which 
often leads to complex instructions and reduces dietary adherence.  
 
 Evidence for restricting phosphate 
Restriction of dietary protein, and with it dietary phosphate, slows the progression of renal disease 
in experimental animal models 
8,9
. In humans, elevated phosphate levels are associated with the 
development and progression of CKD-MBD 
10
, but the benefits of intervention to restrict dietary 
protein and phosphate remain unclear. Patients with renal impairment and elevated serum 
phosphate values are at greater risk of coronary artery calcification, cardiovascular disease (CVD), 
progression to end stage renal disease (ESRD), and early mortality 
11-13
. However, the Kidney Early 
Evaluation Program (KEEP) study illustrated that while phosphate levels are associated with these 
outcomes, they are not necessarily causative and may not be true surrogates 
14
. The KEEP 
nationwide study screened high-risk individuals in the USA with estimated glomerular filtration rate 
(eGFR) <60 ml/min per 1.73m
2
, and analysed risk according to quartiles of serum phosphate. 
Individuals in the highest serum phosphate quartile had an unadjusted 6.72-fold higher risk of 
progression to ESRD over a median follow up of 2 years than those with phosphate values of ≤3.3 
mg/dl (the reference value). However, this hazard ratio was no longer significant when adjusted for 
demographic data, other cardiovascular risk factors and severity of CKD. The value of pharmaceutical 
interventions to reduce serum phosphate is even more controversial. When phosphate binder 
effects were studied in moderate CKD 
15
, the risk of developing vascular calcification was greater for 
patients allocated to any type of phosphate binder (lanthanum, sevelamer and calcium-based) than 
to placebo.  
 
Another potential benefit of phosphate restriction and/or phosphate binder use is to ameliorate the 
dramatic rises in FGF23 that occur as CKD progresses. Although early elevations of FGF23 are 
adaptive to maintain phosphate homeostasis, the extreme values found in patients with CKD are 
associated with increased cardiac fibrosis, hypertrophy and arrhythmogenic potential 
16,17
, and with 
increased progression to dialysis and increased mortality in patients with CKD stages 2-4 
18
. 
Consequently, recent studies of protein and phosphate restriction, and of interventions using 
phosphate binding agents, have focussed on FGF23 modulation as a surrogate for the amelioration 
of CVD.   
 
Evidence for patient-level benefits of protein and phosphate restriction in CKD. 
Despite the cost in time and human resources invested in counselling patients on protein and 
phosphate restriction, the evidence for dietary intervention is remarkably poor, and even in clinical 
trials, up to 50% of patients fail to achieve dietary compliance. Table 1 summarises important 
studies, most of which are randomised, controlled trials, of usual versus reduced dietary 




The Modification of Diet in Renal Disease (MDRD) study 
20
, was a major initiative to assess decline in 
kidney function in relation to three levels of protein and phosphate intake (normal, low and very 
low), and two levels of blood pressure management. In the primary analysis, there were no 
statistically significant differences in progression between low and usual protein diets, or between 
low and very low protein diets. The authors concluded that the effect of these dietary prescriptions 
to patients with mild to moderate renal insufficiency remained uncertain. Further analysis suggested 
that lower protein diets might slow progression in patients with the most rapid decline in GFR 
21
 and 
each decrease in protein intake of 0.2 g/kg/day was associated with a slower mean GFR decline 
22
. As 
a result, the authors suggested a prescribed dietary protein intake of 0.8 g/kg/day for patients with  
GFR < 25 mL/min/1.73 m
2
.    
 
Pedrini et al 
23
 performed a systematic review of studies to December 1994 that assessed usual 
versus low protein dietary restriction in patients with moderate CKD (eGFR <55 ml/min/1.73m
2
). 
That meta-analysis indicated significantly less progression of renal impairment in both non diabetic 
and type 1 diabetic patients allocated to low protein diets. In five studies of non diabetic renal 
impairment, the relative risk (RR) for renal failure or death was 0.67 (95% Cl, 0.50 to 0.89), and in the 
five studies of patients with type-1 diabetes mellitus a low-protein diet significantly slowed increases 
in urinary albumin and the decline in GFR or creatinine clearance [RR, 0.56 (Cl, 0.40 to 0.77)].  
Moe et al
5
 investigated differences in phosphate absorption between grain-based and meat-based 
diets that contained equivalent protein and phosphate, and observed higher levels of serum 
phosphate and FGF23 and lower PTH levels after one week of the meat-based diet. Most recently, a 
long term follow up of patients enrolled in the MDRD study 
24
 reported that pre-randomisation 
urinary phosphate levels were not associated with long-term outcomes of ESRD or mortality, 
although in a fully adjusted model a three-day dietary recall for phosphate did show a modest 
association to all-cause mortality. The authors suggested that until further studies confirmed or 
refuted their findings, caution should be used in advising reductions in dietary phosphate and 
protein intake in patients with CKD. The chance of such a study is remote.  
 
Improving the management of phosphate control; ‘What you eat today walks and talks 
tomorrow’. 
In 2013, Dr Tonelli writing in Kidney International
25
, suggested that a smart phone ‘food switch’ 
application (app.) could be developed for patients with CKD to help them control their phosphate 
levels. After scanning the bar code of a product, the app. would provide information on the 
phosphate content (inclusive of additives) of the selected and comparable products, so that 
consumers could make a more informed choice. Of course, this relies on the availability of an 
extensive, locally germane food database. With this in mind, we approached the developers of the 
most downloaded, free of charge Australian dietary app. to create a version containing information 
applicable to patients with CKD. The app. contained information on over 50,000 Australian foods 
obtained from Australian food databases and food product labels. Patients using the app. could elect 
to share data collected by the app. with their dietitian or other health professionals, to enable real-
time online monitoring of their progress. When released for download, the new renal version (Easy 
Diet Diary Renal™) included dietary phosphate, sodium, calcium and potassium, in addition to 
protein, kilojoules and carbohydrate.  
 
Efficacy and acceptance of a renal app. for dietetic monitoring; a pilot study.  
To compare the utility of the app. to standard dietetic monitoring, we undertook a pilot study with 
approval of the Human Research Ethics Committee of Western Sydney Local Health District and 
adherence to the Declaration of Helsinki (ACTRN12617000558325).   
Methods: After providing volunteers with study information and receiving their informed consent, 
25 participants with a normal urinalysis, blood pressure and without a history of kidney disease or 
use of medications likely to influence urinary sodium or phosphate values were randomly allocated 
to an intervention or a control group. Next, all participants maintained a food diary for 3 days to 
assess baseline dietary sodium and phosphate intakes, followed by a 24 hour urine sample for 
volume, creatinine, sodium and phosphate. Participants were then requested to moderately reduce 
their sodium and phosphate intake for two weeks, to daily targets often used for people with 
established renal failure (ERF) of <100 mmol sodium and < 1000 mg phosphate. To achieve this, all 
participants were provided with a dietary leaflet used in normal clinical care that provided advice on 
strategies to achieve the reduction.  Based on the dietary records, participants were given feedback 
on their dietary intakes of sodium and phosphate, and provided with individualised advice on 
reducing that intake to within the target range in a telephone interview of no more than 1 hour with 
a trained dietician. No additional strategies were used in the control group. However, the 
intervention group were given approximately 30 minutes instruction by a non-dietician on use of the 
dietary app. to monitor sodium and phosphate targets.  
The primary outcome was to assess within group change in 24 hour urinary phosphate and sodium 
values between collections at baseline and two weeks after commencement of the diet. The 
estimated sample size for this was 10 participants per arm. Calculation of between group differences 
(estimated sample size 123 subjects per arm) was outside the scope of this pilot study. The 
secondary outcome was to compare ease of dietary compliance between the groups using a 
questionnaire completed by all participants at the conclusion of the dietary intervention. The 
questionnaire included 11 questions on acceptability and usability of the food diary, five on 
compliance, five free text questions and for app. users, 14 questions on ease of use.  
Paired t-tests or Wilcoxon signed rank tests were used to test for differences between baseline and 
end of the intervention. Independent t-tests or Wilcoxon rank sum tests were used to test for 
differences between groups. Analyses were conducted by intention to treat and significance was 
determined by p-values <0.05. Questionnaire responses were recorded by participants using a 5-
point Likert scale. Statistical analyses were undertaken using SPSS version 21 (SPSS Inc., Chicago, 
Illinois, USA).  
Results: Participant demographics and clinical details, dietary intakes calculated from the three day 
food diaries and baseline 24 hour urinary values for sodium, phosphate and creatinine did not differ 
significantly between groups (Table 2). Baseline sodium and phosphate intakes from the three day 
dietary assessments were close to the 50
th
 percentile of age adjusted population norms . However, 
24 hour urinary values of sodium and phosphate, measured as a single batch after conclusion of the 
study, were close to the targeted range even before any dietary intervention (Table 2). Comparison 
of pre and post intervention urinary values indicated trends to reduction in mean sodium and 
phosphate values that did not reach statistical significance within or between groups (Table 2) or 
when values for the control and app. group were combined to assess change over the period of 
dietary intervention. Comparing questionnaire responses, app. users referred to information on the 
app. more frequently than the control group participants referred to written instructions, app. users 
found referring to the app. more convenient, felt they learned more new information, were more 
motivated to maintain the diet and were more likely to recommend their information source to 
family or friends (all p<0.05), with trends to confidence in improving eating habits (p=0.06), ease of 
use (p=0.07) and fewer non-compliant days (p=0.08) (Table 2) . In the free text section, six control 
participants felt they lacked access to sufficient information, while no app. users indicated that they 
lacked information. 
Discussion: The pilot study suggested that participants using the app., which gave them immediate 
access to the sodium, phosphate, potassium and nutrient content of their foods, had a better 
experience of the restricted diet. Their greater motivation and self assessed increase in knowledge 
of food sources was encouraging. These results can be contrasted with a study of 279 patients in 14 
long-term dialysis facilities with persistently elevated phosphate levels
26
.  Patients were allocated to 
usual care or intervention that included specific instruction, handouts of preferred foods and foods 
to avoid and additional telephone reinforcement. Serum phosphate levels decreased at three 
months in the intervention group and food knowledge scores improved in both. However, there was 
no significant difference in food knowledge between control and interventional groups as noted in 
our study.    Nevertheless, it is important to emphasise that before use of the app. can be endorsed 
in research or with groups such as patients with CKD, further studies would be required to 
determine whether the app. assists these patients to achieve their nutrient targets.   
The renal app. is now available in Australasia, with approximately 450 downloads in the first six 
months since its release. A screen shot of a sample breakfast is included (Figure 1). Further 
modifications will differentiate foods high in organic and inorganic phosphate and provide the ‘food 
switch’ capacity suggested by Dr. Tonelli in 2013.  
 
Conclusion. 
In ESRD, when phosphate homeostasis is no longer attainable through endogenous responses, a low 
phosphate, high protein intake has been associated with reduced mortality, but extremely low 
dietary phosphate combined with a low protein intake may produce worse outcomes. This equipoise 
is not achieved by many patients. Based on the available evidence, encouragement to eat grain and 
vegetable-based meals with lower inorganic phosphate, reduced phosphate additives and high-value 
protein is unlikely to have adverse effects and may have benefits for most people with CKD. Reduced 
reliance on calcitriol or other VDRAs to suppress PTH, and an acceptance of moderately increased 
PTH levels in the later stages of CKD, will also lead to reduced intestinal phosphate absorption and 
may improve phosphate balance. Although based on weak clinical evidence, it appears preferable to 
target treatment towards overt hyperphosphatemia in CKD stages 3-5, rather than targeting values 
of serum phosphate in the normal range. As well as being more attainable, this would reduce 
adverse effects of phosphate binder therapy, including hypercalcaemia associated with calcium-
based binders. Public advocacy for the disclosure on packaged food labels of all phosphate additives, 
which are the source of highly absorbed phosphate, would be a real benefit to consumers. In 
addition, a renal dietary app. may encourage some users to understand and improve their food 
choices and dietary compliance.  
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Legend to tables 1 and 2 and to figure 1.  
 
Table 1.   Studies comparing diets containing usual versus reduced phosphate and protein. Abbreviations; CKD: chronic kidney disease, DM: diabetes 
mellitus, P: phosphate, BP: blood pressure, tHcy: total homocysteine, Na: sodium, PTH: parathyroid hormone, BMI: body mass index, FGF23: fibroblast 
growth factor 23, 25OHD: 25-hydroxyvitamin D, 1,25(OH)2D: 1,25-dihydroxyvitamin D, Ca: calcium, ESRD: end-stage kidney disease, CV: cardiovascular, HR: 
hazard ratio, SD: standard deviation, CI: confidence interval.  
 
Table 2. Participant demographics, dietary intakes calculated from three-day food records, pre and post study values for 24 hour urine biochemistry and 
selected questionnaire responses. * p<0.05 for between group differences.   
For the general population aged 19 to 30 years, the 50
th
 percentile for usual daily sodium intake, excluding discretionally added salt, is 2247 mg for females 
and 2965 mg for males and for phosphorus is 1228 mg for females and 1695 mg for males 
(http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.008~2011-12~Main%20Features~Essential%20minerals~400; accessed 
September 2017). Based on the three day food diary prior to dietary intervention, 33 % of participants had sodium intakes within the target range, while 
33% of control group participants had phosphate intakes within the target range. However, based on urinary sodium and phosphate values, 33% and 54% of 
participants had baseline sodium values within the target range and 92% and100% had baseline phosphate values within the target range before dietary 
intervention.  Baseline and end of study urinary values were determined after study completion.  
 






Author and year 
Hypothesis 
Number available for 
analysis    
Study 
duration  




Active intervention      Primary outcome    Secondary  outcomes 
 
Pedrini et al 
23
, 1996 




Protein and P restriction 
may prevent or delay 
worsening of CKD 
1413 non diabetic 




108 patients with type 1 







<55  Low protein: 0.4-0.6 




Low protein 0.50 
g/kg/ day - 0.85 
g/kg/day 
Progression of renal 
disease 27% lower 
in patients on low 
protein diet  
Benefit of low protein 
diet not related to BP 
lowering 





Rate of decline in kidney 
function will be modified 
by protein, P restriction 
and BP control 
 














 Mean 2.2 
years 






Study B: 13-24 
Study A: usual-
protein (1.3 g/kg 
day) vs. low-protein 
(0.58 g/kg/day}, P 5-
10 mg/kg/day 
 
Study B: Low-protein 
0.58 g/kg/day, P: 5-
10 mg/kg/day 
vs. very low-protein 
0.28 g/kg/day + keto 
acids-amino acids 
0.28 g/kg/day and 
P 4-9 mg/kg/day 
Study A: Projected 
decline in GFR at 3 
years did not differ 
between diet groups 
 
 
Study B: Trend (p = 
0.07) toward  slower 
mean decline in GFR 
with very low-
protein diet.  
No significant effect 
on time to renal 
failure / death. 
 





Rate of decline in kidney 
function will be modified 
by protein and P 
restriction and BP 
control 
 
574 3 years Study A: 25-55 
 
Three levels of 
protein and P intake 
and two levels of BP 
management 
Low-protein: 0.58 
g/kg per day 
Usual protein: 1.3 
g/kg day 
Effect of low-protein 
diet inconclusive 
due to nonlinear 
GFR decline and 
limited duration of 
follow-up 
Faster GFR decline on 
low-protein diet in 1st  4 
months, then slower 
decline 
No difference between 
dietary groups over 3 
years 
Possible beneficial effect 
of low- protein diet to 
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 slow GFR decline in 
patients with the most 
rapidly declining GFR, and 







Rate of decline in kidney 
function will be modified 
by protein restriction 






Study B: 13-24  Prescribed diets for 
Study B as above 
Reanalysis using 
achieved  protein 
intake calculated 




Low 0.73 g/kg/day  
Very low 0.66 
g/kg/day 
 






Risk of developing end 
stage renal disease or 
death within 3 years of 
follow-up: 51% for 0.8 
g/kg/day vs.30% for 0.6 
g/kg/day (a 40% 
reduction) 
No relationship of 
protein intake to change 
in urine protein excretion 
Keto acid-amino acid 







High protein intake will 
be associated with 
higher tHcy 
678 1 year 13-24 
25-55 
Dietary protein  
low vs. usual  
Dietary protein low 
vs. very low + amino 
acids and ketoacids  
No association of 
protein intake to 
tHcy values. 
Vitamin supplementation 






Low protein intake will 
improve nitrogen waste 
products retention and 
calcium, P and acid-base 
disturbances 
53 48 weeks <30 
 





mixed protein diet 
0.6 g/kg/day  
Significantly higher 
serum bicarbonate 
and lower serum P 
in the very low 
group 
No death in either group  
No significant change in 
eGFR for very low group 
Fewer patients in the very 
low group progressed to 
dialysis; 4% vs. 27% 
Limitations; small 







392 6-18 months 18±7 
CKD stages 4-5 
Usual and low 
protein diets: 0.80 
vs. 0.55 g/kg/day + 
Significant between-
group difference in 
protein intake  
Compliance: 27% for 
0.55g and 53% for 0.8g 




Low protein will modify 
serum urea nitrogen 
concentration 
multivitamin and 
mineral tablet daily + 




were used to achieve 
K/DOQI targets 
No significant 
difference in blood 
urea for intention to 
treat 
Increased urea with 
higher protein in per 
protocol analysis 
in serum P/PTH/ 
bicarbonate or 
progression of renal 
failure in intention to 
treat or per protocol 
analyses 
Lower urinary P and Na 
and less P binder use in 
low protein group 
No change in BMI or body 
weight over time, 
including patients strictly 





Vegetarian or meat 
protein sources affect 
levels of serum P and 
FGF23  
8 (crossover) 1 week then  




25-40  Grain/soy 
(vegetarian) or 
meat/dairy (meat); 
equivalent content of 
protein and P 800 
mg/day  
No preservative 
After 1 week meat 
vs. vegetable diet, 
higher P, FGF23, and 
trend to urinary P 
and  lower PTH  
 
Correlation of change in 
plasma P and FGF23. No 
relationship to 25OHD, 





Dietary P restriction, the 
P binder lanthanum or 
both will reduce levels of 
FGF23 
16 (2 by 2 factorial) 2 weeks 15-60 750 or 1500 mg 
dietary P daily and 
lanthanum 1g or 
placebo with meals. 
750 mg P added to 
meals 3 times daily 
Neither group had 
lower FGF23 
 
Lower urinary P with 
lower P diet and rise in 
FGF23 with higher P and 
placebo 
No significant changes in 
serum P levels between 
or within the diet or 
binder groups 






Low protein and P will 
reduce levels of FGF23 
 
 
32 (crossover) 2 weeks 21-54  Very-low-protein (0.3 
g/kg per day; 350-
420 mg/day P) vs. 
conventional low 
protein (0.6 g/kg per 
day; 600-700 mg/day 
P)  + ketoanalogues 
FGF23 fell 
significantly by 
33.5% in the very 
low protein/P group 
Lower serum and urine P 
and increased urinary P 
reabsorption. 









Altered dietary protein 
influences FGF23 levels 
18 patients with CKD 
and 12 healthy controls 
(crossover) 
3 weeks 15-60 (CKD group) 
 
High P: 2000 mg/day, 
low P: 750 mg/day, 
low P + 500 mg 
aluminium hydroxide 
three times daily 
Low protein:76 ± 3 
g/day, high protein: 
82 ± 5 g/day 
FGF23 levels 
respond to dietary 
change in CKD 
patients and 
controls 
In patients with CKD and 
controls, higher dietary P 
is associated with  lower 
serum  1,25(OH)2D and 
higher serum P values 






Reduced dietary P plus 
lanthanum carbonate 
will reduce FGF23 from 
baseline 
 
39: 4 groups of 8-10 
patients at study 
completion  
 
12 weeks 15-60 Ad libitum diet or 
900 mg P diet ± three 
times daily 
lanthanum 1000 mg 
or placebo  
P-restricted diet + 
lanthanum reduced 
FGF23 
P-restricted diet  
had borderline 
effect 
No between group 
differences in serum P, 
Ca, PTH, 1,25(OH)2D, 
urinary P 
Urinary P might not be 
useful for monitoring 
adherence or titrating 
interventions aimed at 
reducing FGF23  
No differences in cardiac 
echo parameters 
PTH rose in patients on 





A standard low-protein 
diet reduces FGF23 in 
CKD 
15 (Early CKD)  
20 (Advanced CKD) 
<1 week >60 
<30 
Regular protein; 1.1-
1.4 g/kg/day and 15-
20 mg/kg/day P vs. 
low protein; 0.6-0.8 
g/kg/day and 10-15 
mg/kg/day P   
FGF23 was lower in 
both groups on low 
protein diet 
FGF23 correlated to 
urinary P excretion 
only in patients with 
advanced CKD 
With lower protein diet; 
PTH and P levels fell in 
advanced CKD 
1,25(OH)2D levels 
increased in early CKD  
Urine P decreased in both 
groups 






A relationship exists of 
pre-randomisation 
dietary P, evaluated by 
795 Mean follow 
up 16 years 
(0.25-22) 
33±12 
CKD stages 3-5 
Comparison of 
baseline urinary P 
quartiles and 
outcomes; 589 
progressed to ESRD, 
191 died of CV and 
No statistically 
significant 
associations of 24hr 
urinary P and 
ESRD, CV, non-CV 
and all cause 
A direct association of 3 
day dietary P recall and 
all-cause mortality (HR 
per SD higher 1.19 [95% 
CI 1.03, 1.37], p=0.02) in 
the fully adjusted model 
. 32 
 
24 hour urine P, to risks 
of ESRD and mortality  
 
228 of non-CV causes  
  
mortality in 
minimally or fully 
adjusted models. 
Limitation: baseline 
urinary P may not reflect 





Table 2.  













Baseline demographic and clinical details 
Age median (IQR) 26 (25.5-29.5) 26 (24.5-28.75) - - 
Male sex (n) 4 5 - - 
Weight (kg) median (IQR) 64.4 (55.2-72.5) 59.5 (54.8-66.1) - - 
BMI kg/m2, mean SD 22.56 (2.52) 23.58 (3.06) - - 
Systolic BP mean SD 111 (12) 111 (11) - - 
Diastolic BP mean SD 74 (9) 69 (10) - - 
Daily intakes calculated from 3 day dietary analyses (mean±SD) 
Baseline vales are prior to dietary interventions  
Dietary sodium 
(1 mmol sodium=23 mg) 
119 (41) mmol  
2734 (941) mg 
116 (32) mmol 
2665 (732) mg 
- - 
Participants (%) with dietary sodium estimation <100 
mmol/day (2300 mg/day)  
33 33   
Dietary phosphate 
(1 mmol phosphorus=31 mg) 
50 (14) mmol 
1554 (430) mg 
42 (13) mmol 
1305 (412) mg 
- - 




0 33   
Protein g/day 100 (26) 88 (30) - - 
Energy kJ/day 9306 (2092) 8714 (2343) - - 
24 hour urine biochemistry (mean±SD) 
Baseline values are prior to dietary intervention  
Urinary sodium 
 
134 (62) mmol 
3082 (1426) mg 
126 (37) mmol 
2898 (851) mg 
114 (62) mmol 
2622 (1426) mg 
123 (38) mmol 
2829 (874) mg 
Participants (%) with urinary sodium <100 mmol/day 
(2300 mg/day)  
54% 33% 75% 33% 
Urinary phosphate  
 
27 (11) mmol 
837 (326) mg 
24 (5) mmol 
744 (155) mg 
25 (12) mmol 
 
20 (6)mmol 
Participants (%) with urinary phosphate <1000 mg/day 
(32.3 mmol/day)  
92 100 83 100 
Urinary calcium  4.2 (1.7) mmol 3.4 (1.5) mmol 3.4 (2.5) mmol 3.4 (1.4) mmol 
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 168 (68) mg 136 (45) mg 136 (100) mg 136 (56) mg 
Urinary creatinine 13.1 (6.6) mmol 11.1 (3.0)   
Post study evaluation questionnaire responses 
Number of days of non-compliance to the diet over the 
past 2 weeks (Mean±SD) 
- - 2.6 (1.7) 4.9 (4.1)  
Proportion (%) who agreed the supplementary 
information/app. increased their motivation to adhere to 
the diet 
- - 50* 25 
Number of times referring to supplementary diet 
information/app. [Median (IQR] 
- - 3.5 (2-3)* 2 (1.3-3) 
Proportion (%) who agreed the supplementary 
information/app. increased their knowledge  
- - 92* 54 
Proportion (%) who agreed the supplementary 
information/app. increased their confidence about 
following the diet 
- - 50* 25 
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Figure 1. 
